These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure. Stein G; Sierakowski B; Grass P; Haufe CC; Jansa U; Weidinger G Blood Press Suppl; 1994; 2():47-53. PubMed ID: 8061846 [TBL] [Abstract][Full Text] [Related]
4. A randomized and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension. Petersen LJ; Petersen JR; Talleruphuus U; Møller ML; Ladefoged SD; Mehlsen J; Jensen HA Clin Nephrol; 2001 May; 55(5):375-83. PubMed ID: 11393383 [TBL] [Abstract][Full Text] [Related]
5. [Spirapril in the therapy of mild and moderately severe hypertension. A Czech and Slovak multicenter study]. Widimský J; Lánská V; Hulínský V Vnitr Lek; 1995 Nov; 41(11):744-52. PubMed ID: 8553592 [TBL] [Abstract][Full Text] [Related]
6. Concomitant administration of isradipine and spirapril prevents reduction of renal function induced by acute administration of spirapril in patients with reduced renal function. Wittenberg C; Erman A; Shohat J; Boner G Blood Press Suppl; 1994; 1():48-9. PubMed ID: 8205299 [TBL] [Abstract][Full Text] [Related]
7. Single daily administration of spirapril in the treatment of essential hypertension. A multicentre double-blind comparison of 1, 6, 12 and 24 mg of spirapril once daily. Hayduk K; Schardt F; Sierakowski B; Weidinger G; Welzel D Blood Press Suppl; 1994; 2():41-6. PubMed ID: 8061845 [TBL] [Abstract][Full Text] [Related]
8. Effects of angiotensin converting enzyme inhibitor on renal function in patients of membranoproliferative glomerulonephritis with mild to moderate renal insufficiency. Giri S; Mahajan SK; Sen R; Sharma A J Assoc Physicians India; 2002 Oct; 50():1245-9. PubMed ID: 12568207 [TBL] [Abstract][Full Text] [Related]
9. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: does it exist and does it affect the antihypertensive response? van den Meiracker AH; Man in 't Veld AJ; Admiraal PJ; Ritsema van Eck HJ; Boomsma F; Derkx FH; Schalekamp MA J Hypertens; 1992 Aug; 10(8):803-12. PubMed ID: 1325513 [TBL] [Abstract][Full Text] [Related]
10. Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension. Noble S; Sorkin EM Drugs; 1995 May; 49(5):750-66. PubMed ID: 7601014 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of delapril plus manidipine compared with enalapril plus hydrochlorothiazide in mild to moderate essential hypertension: results of a randomized trial. Mugellini A; Dobovisek J; Planinc D; Cremonesi G; Fogari R Clin Ther; 2004 Sep; 26(9):1419-26. PubMed ID: 15531004 [TBL] [Abstract][Full Text] [Related]
12. A multicentre multidose study of the efficacy and safety of spirapril in mild-to-moderate essential hypertension. UK Study Group of Spirapril in Hypertension. Fairhurst GJ Blood Press Suppl; 1994; 2():77-80. PubMed ID: 8061852 [TBL] [Abstract][Full Text] [Related]
13. 24-hour ambulatory blood pressure monitoring and spirapril in mild to severe essential hypertension: a randomized dose comparison. Vreugdenhil G; van Montfrans GA; Jacobs MC; de Bruijn JH; Veerman DP; van Es PN; Mellein B; Guitard C; Thien T; de Leeuw PW Blood Press Suppl; 1994; 2():23-30. PubMed ID: 8061842 [TBL] [Abstract][Full Text] [Related]
14. ACE-inhibitor therapy with spirapril increases nocturnal hypotensive episodes in elderly hypertensive patients. Kantola I; Terént A; Kataja M; Breig-Asberg E J Hum Hypertens; 2001 Dec; 15(12):873-8. PubMed ID: 11773991 [TBL] [Abstract][Full Text] [Related]
16. Placebo-controlled crossover comparison of spirapril at 3, 6, 12 and 24 mg once daily in mild to severe essential hypertension. Guitard C; Sassano P; Tzincoca C; Duchiez J; Safar ME Blood Press Suppl; 1994; 2():61-8. PubMed ID: 8061848 [TBL] [Abstract][Full Text] [Related]
17. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548 [TBL] [Abstract][Full Text] [Related]
18. [Spirapril - a new long-acting ACE inhibitor: efficacy and safety in patients with arterial hypertension in combination with diabetes mellitus and impaired kidney function]. Iakusevich VV; Mozheĭko ME; Paliutin ShKh; Berezina MIu; Martsevich SIu; Shal'nova SA; Deev AD; Kutishenko NP; Alimova EV; Koniakhina IP; Semenova IuE Ter Arkh; 2000; 72(10):82-6. PubMed ID: 11220887 [TBL] [Abstract][Full Text] [Related]
19. [A Czech and Slovak interventional study of spirapril (the CASSIS study). A randomized, double-blind, multicenter, placebo-controlled study in chronic heart failure]. Jerie P; Kremer HJ; Uhlír O; Widimský J Vnitr Lek; 1997 Jun; 43(6):351-8. PubMed ID: 9601863 [TBL] [Abstract][Full Text] [Related]
20. A randomized, controlled, multicenter study to compare prazosin GITS with enalapril in hypertensive patients with diabetes mellitus. Bombay Hypertension Study Group. Joglekar SJ; Nanivadekar AS J Assoc Physicians India; 1998; Suppl 1():52-62. PubMed ID: 11233387 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]